Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

British Journal of Haematology

Volumn 139, Issue 1, 2007, Pages 70-80

  Peggs, Karl S ^a   Sureda, Anna ^a   Qian, Wendi ^a   Caballero, Dolores ^a   Hunter, Ann ^a   Urbano Ispizua, Alvaro ^a   Cavet, James ^a   Ribera, Josep M ^a   Parker, Anne ^a   Canales, Miguel ^a   Mahendra, Premini ^a   Garcia Conde, Javier ^a   Milligan, Donald ^a   Sanz, Guillermo ^a   Thomson, Kirsty ^a   Arranz, Reyes ^a   Goldstone, Anthony H ^a   Alvarez, Ivan ^a   Linch, David C ^a   Sierra, Jorge ^a   MacKinnon, Stephen ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic transplantation; Hodgkin lymphoma; Reduced intensity; T cell depletion

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUDARABINE; FOLINIC ACID; MELPHALAN; METHOTREXATE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LYMPHOCYTE TRANSFUSION; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MALE; MELPHALAN; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 34548544801     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06759.x     Document Type: Article

References (39)

1. Akpek, G., Ambinder, R.F., Piantadosi, S., Abrams, R.A., Brodsky, R.A., Vogelsang, G.B., Zahurak, M.L., Fuller, D., Miller, C.B., Noga, S.J., Fuchs, E., Flinn, I.W., O'Donnell, P., Seifter, E.J., Mann, R.B. Jones, R.J. (2001) Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. Journal of Clinical Oncology, 19, 4314 4321.
2. Alvarez, I., Sureda, A., Caballero, M.D., Urbano-Ispizua, A., Ribera, J.M., Canales, M., Garcia-Conde, J., Sanz, G., Arranz, R., Bernal, M.T., dela, S.J., Diez, J.L., Moraleda, J.M., Rubio-Felix, D., Xicoy, B., Martinez, C., Mateos, M.V. Sierra, J. (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biology of Blood and Marrow Transplantation, 12, 172 183.
3. Anderlini, P. Champlin, R.E. (2006) Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand? Biology of Blood and Marrow Transplantation, 12, 599 602.
4. Anderlini, P., Giralt, S., Andersson, B., Ueno, N.T., Khouri, I., Acholonu, S., Cohen, A., Korbling, M.J., Manning, J., Romaguera, J., Sarris, A., Rodriguez Hagemeister, F., McLaughlin, P., Cabanillas, F. Champlin, R.E. (2000) Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplantation, 26, 615 620.
5. Anderlini, P., Acholonu, S.A., Okoroji, G.J., Andersson, B.S., Couriel, D.R., DeLima, M.J., Donato, M.L., Khouri, I.F., Giralt, S.A., Ueno, N.T. Champlin, R.E. (2004) Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplantation, 34, 511 514.
6. Anderlini, P., Saliba, R., Acholonu, S., Okoroji, G.J., Donato, M., Giralt, S., Andersson, B., Ueno, N.T., Khouri, I., de Lima, M., Hosing, C., Cohen, A., Ippoliti, C., Romaguera, J., Rodriguez, M.A., Pro, B., Fayad, L., Goy, A., Younes, A. Champlin, R.E. (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplantation, 35, 943 951.
7. Anderson, J.E., Litzow, M.R., Appelbaum, F.R., Schoch, G., Fisher, L.D., Buckner, C.D., Petersen, F.B., Crawford, S.W., Press, O.W., Sanders, J.E., Bensinger, W.I., Martin, P.J., Storb, R., Sullivan, K.M., Hansen, J.A. Thomas, E.D. (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. Journal of Clinical Oncology, 11, 2342 2350.
8. Baron, F., Storb, R., Storer, B.E., Maris, M.B., Niederwieser, D., Shizuru, J.A., Chauncey, T.R., Bruno, B., Forman, S.J., McSweeney, P.A., Maziarz, R.T., Pulsipher, M.A., Agura, E.D., Wade, J., Sorror, M., Maloney, D.G. Sandmaier, B.M. (2006) Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology, 24, 4150 4157.
9. Carella, A.M., Cavaliere, M., Lerma, E., Ferrara, R., Tedeschi, L., Romanelli, A., Vinci, M., Pinotti, G., Lambelet, P., Loni, C., Verdiani, S., DeStefano, F., Valbonesi, M. Corsetti, M.T. (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. Journal of Clinical Oncology, 18, 3918 3924.
10. Carella, A.M., Beltrami, G., Carella, M. Jr., Corsetti, M.T., Scalzulli, R.P. Greco, M. (2001) Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease. Haematologica, 86, 1121 1123.
11. Claviez, A., Klingebiel, T., Beyer, J., Nurnberger, W., Ehninger, G., Suttorp, M., Dreger, P., Dorffel, W. Schmitz, N. (2003) Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Annals of Hematology, 83, 237 241.
12. Diaconescu, R., Flowers, C.R., Storer, B., Sorror, M.L., Maris, M.B., Maloney, D.G., Sandmaier, B.M. Storb, R. (2004) Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood, 104, 1550 1558.
13. Drobyski, W.R., Hessner, M.J., Klein, J.P., Kabler-Babbitt, C., Vesole, D.H., Margolis, D.A. Keever-Taylor, C.A. (1999) T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood, 94, 434 441.
14. Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., Potter, M., Pagliuca, A., Ho, A., Devereux, S., McQuaker, G., Mufti, G., Yin, J.L. Russell, N.H. (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 103, 428 434.
15. Gajewski, J.L., Phillips, G.L., Sobocinski, K.A., Armitage, J.O., Gale, R.P., Champlin, R.E., Herzig, R.H., Hurd, D.D., Jagannath, S., Klein, J.P., Lazarus, H.M., McCarthy, Jr., P.L., Pavlovsky, S., Peterson, F.B., Rowlings, P.A., Russell, J.A., Silver, S.M., Vose, J.M., Wiernik, P.H., Bortin, M.M. Horowitz, M.M. (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. Journal of Clinical Oncology, 14, 572 578.
16. Johnston, L.J. Horning, S.J. (2000) Autologous hematopoietic cell transplantation in Hodgkin's disease. Biology of Blood and Marrow Transplantation, 6, 289 300.
17. Jones, R.J., Ambinder, R.F., Piantadosi, S. Santos, G.W. (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood, 77, 649 653.
18. Josting, A., Rueffer, U., Franklin, J., Sieber, M., Diehl, V. Engert, A. (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood, 96, 1280 1286.
19. Klein, J.P., Rizzo, J.D., Zhang, M.J. Keiding, N. (2001a) Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling. Bone Marrow Transplantation, 28, 1001 1011.
20. Klein, J.P., Rizzo, J.D., Zhang, M.J. Keiding, N. (2001b) Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplantation, 28, 909 915.
21. Kolb, H.J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. Wilmanns, W. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462 2465.
22. Lunn, M. McNeil, D. (1995) Applying Cox regression to competing risks. Biometrics, 51, 524 532.
23. Mackinnon, S., Barnett, L., Heller, G. O'Reilly, R.J. (1994) Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood, 83, 3409 3416.
24. Mapara, M.Y., Kim, Y.M., Wang, S.P., Bronson, R., Sachs, D.H. Sykes, M. (2002) Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood, 100, 1903 1909.
25. Marshall, N.A., Christie, L.E., Munro, L.R., Culligan, D.J., Johnston, P.W., Barker, R.N. Vickers, M.A. (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood, 103, 1755 1762.
26. Milpied, N., Fielding, A.K., Pearce, R.M., Ernst, P. Goldstone, A.H. (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for blood and bone marrow transplantation. Journal of Clinical Oncology, 14, 1291 1296.
27. Morris, E.C., Rebello, P., Thomson, K.J., Peggs, K.S., Kyriakou, C., Goldstone, A.H., Mackinnon, S. Hale, G. (2003) Pharmacokinetics of alemtuzumab (CAMPATH-1H) used for in vivo and in vitro T-cell depletion in allogeneic transplants: relevance for early adoptive immunotherapy and infectious complications. Blood, 102, 404 406.
28. Peggs, K.S., Hunter, A., Chopra, R., Parker, A., Mahendra, P., Milligan, D., Craddock, C., Pettengell, R., Dogan, A., Thomson, K.J., Morris, E.C., Hale, G., Waldmann, H., Goldstone, A.H., Linch, D.C. Mackinnon, S. (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, 365, 1934 1941.
29. Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., SanMiguel, J.F. Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100, 3121 3127.
30. Porter, D.L., Connors, J.M., VanDeerlin, V.M., Duffy, K.M., McGarigle, C., Saidman, S.L., Leonard, D.G. Antin, J.H. (1999) Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. Journal of Clinical Oncology, 17, 1234 1243.
31. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. Thomas, E.D. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825 828.
32. Robinson, S.P., Schmitz, N., Taghipour, G. Sureda, A. (2004) Reduced intensity allogeneic stem cell transplantation for Hodgkin's disease. Outcome depends primarily on disease status at time of transplantation. Blood (ASH Annual Meeting Abstracts), 104, 2322.
33. Salisbury, J.R., Rapson, N.T., Codd, J.D., Rogers, M.V. Nethersell, A.B. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. Journal of Clinical Pathology, 47, 313 317.
34. Schmitz, N. Sureda, A. (2005) The role of allogeneic stem-cell transplantation in Hodgkin's disease. European Journal of Haematology, 75 (Suppl. 66 146 149.
35. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Muller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359, 2065 2071.
36. Shaw, B., Byrne, J., Das-Gupta, E., Carter, I. Russell, N.H. (2005) Converting mixed chimerism to full donor chimerism in recipients of campath-containing reduced intensity transplants reduces the relapse risk and results in significantly improved survival compared to those with persistent full donor chimerism. Blood (ASH Annual Meeting Abstracts), 106, 2026.
37. Sullivan, K.M., Shulman, H.M., Storb, R., Weiden, P.L., Witherspoon, R.P., McDonald, G.B., Schubert, M.M., Atkinson, K. Thomas, E.D. (1981) Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood, 57, 267 276.
38. Sureda, A. Schmitz, N. (2002) Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease. Annals of Oncology, 13 (Suppl. 1 128 132.
39. Tarella, C., Cuttica, A., Vitolo, U., Liberati, M., DiNicola, M., Cortelazzo, S., Rosato, R., Rosanelli, C., DiRenzo, N., Musso, M., Pavone, E., Santini, G., Pescarollo, A., DeCrescenzo, A., Federico, M., Gallamini, A., Pregno, P., Romano, R., Coser, P., Gallo, E., Boccadoro, M., Barbui, T., Pileri, A., Gianni, A.M. Levis, A. (2003) High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer, 97, 2748 2759.